Prothena Corporation plc 0PT.F Stock
Prothena Corporation plc Price Chart
Prothena Corporation plc 0PT.F Financial and Trading Overview
| Prothena Corporation plc stock price | 21.6 EUR |
| Previous Close | 65.5 EUR |
| Open | 66 EUR |
| Bid | 66 EUR x 10000 |
| Ask | 66.5 EUR x 10000 |
| Day's Range | 66 - 66.5 EUR |
| 52 Week Range | 21.6 - 71 EUR |
| Volume | 100 EUR |
| Avg. Volume | 6 EUR |
| Market Cap | 3.58B EUR |
| Beta (5Y Monthly) | 0.360211 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.57 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.75 EUR |
0PT.F Valuation Measures
| Enterprise Value | 2.8B EUR |
| Trailing P/E | N/A |
| Forward P/E | -29.295155 |
| PEG Ratio (5 yr expected) | -83.83 |
| Price/Sales (ttm) | 65.26992 |
| Price/Book (mrq) | 5.7670627 |
| Enterprise Value/Revenue | 50.988 |
| Enterprise Value/EBITDA | -18.772 |
Trading Information
Prothena Corporation plc Stock Price History
| Beta (5Y Monthly) | 0.360211 |
| 52-Week Change | 203.24% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 71 EUR |
| 52 Week Low | 21.6 EUR |
| 50-Day Moving Average | 56.57 EUR |
| 200-Day Moving Average | 51.46 EUR |
0PT.F Share Statistics
| Avg. Volume (3 month) | 6 EUR |
| Avg. Daily Volume (10-Days) | 7 EUR |
| Shares Outstanding | 52.75M |
| Float | 38.68M |
| Short Ratio | N/A |
| % Held by Insiders | 4.72% |
| % Held by Institutions | 95.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -232.19% |
| Operating Margin (ttm) | -273.0069% |
| Gross Margin | -178.68% |
| EBITDA Margin | -271.61% |
Management Effectiveness
| Return on Assets (ttm) | -14.16% |
| Return on Equity (ttm) | -24.37% |
Income Statement
| Revenue (ttm) | 54.92M EUR |
| Revenue Per Share (ttm) | 1.13 EUR |
| Quarterly Revenue Growth (yoy) | 88.09% |
| Gross Profit (ttm) | -81657000 EUR |
| EBITDA | -149175008 EUR |
| Net Income Avi to Common (ttm) | -127523000 EUR |
| Diluted EPS (ttm) | -2.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 686.18M EUR |
| Total Cash Per Share (mrq) | 13.01 EUR |
| Total Debt (mrq) | 4.89M EUR |
| Total Debt/Equity (mrq) | 0.8 EUR |
| Current Ratio (mrq) | 14.327 |
| Book Value Per Share (mrq) | 11.531 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -118864000 EUR |
| Levered Free Cash Flow (ttm) | -42870248 EUR |
Profile of Prothena Corporation plc
| Country | Germany |
| State | N/A |
| City | Dublin |
| Address | 77 Sir John Rogerson’s Quay |
| ZIP | 2 |
| Phone | 353 1 236 2500 |
| Website | https://www.prothena.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 127 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Q&A For Prothena Corporation plc Stock
What is a current 0PT.F stock price?
Prothena Corporation plc 0PT.F stock price today per share is 21.6 EUR.
How to purchase Prothena Corporation plc stock?
You can buy 0PT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prothena Corporation plc?
The stock symbol or ticker of Prothena Corporation plc is 0PT.F.
Which industry does the Prothena Corporation plc company belong to?
The Prothena Corporation plc industry is Biotechnology.
How many shares does Prothena Corporation plc have in circulation?
The max supply of Prothena Corporation plc shares is 53.72M.
What is Prothena Corporation plc Price to Earnings Ratio (PE Ratio)?
Prothena Corporation plc PE Ratio is now.
What was Prothena Corporation plc earnings per share over the trailing 12 months (TTM)?
Prothena Corporation plc EPS is -2.57 EUR over the trailing 12 months.
Which sector does the Prothena Corporation plc company belong to?
The Prothena Corporation plc sector is Healthcare.